GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (NAS:IONS) » Definitions » Total Inventories

Ionis Pharmaceuticals (Ionis Pharmaceuticals) Total Inventories : $28.4 Mil (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Total Inventories?

Ionis Pharmaceuticals's total inventories for the quarter that ended in Dec. 2023 was $28.4 Mil. Ionis Pharmaceuticals's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $27.0 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Ionis Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-1.79.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Ionis Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 was 805.50.

Inventory Turnover measures how fast the company turns over its inventory within a year. Ionis Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.11.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Ionis Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.08.


Ionis Pharmaceuticals Total Inventories Historical Data

The historical data trend for Ionis Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Total Inventories Chart

Ionis Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.18 21.97 24.81 22.03 28.43

Ionis Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.03 22.20 25.54 25.63 28.43

Ionis Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Ionis Pharmaceuticals  (NAS:IONS) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Ionis Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(2331.201+0.75 * 0+0.5 * 28.425-2603.386
-0-0)/144.341
=-1.79

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Ionis Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=27.0295/3.062*365 / 4
=805.50

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Ionis Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=3.062 / 27.0295
=0.11

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Ionis Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=27.0295 / 324.505
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Ionis Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Ionis Pharmaceuticals (Ionis Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Executives
Brian Birchler officer: EVP, Corp and Development Ops C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Patrick R. O'neil officer: SVP, Legal and General Counsel C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Onaiza Cadoret-manier officer: Chief Corp Dev and Cml Officer 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eugene Schneider officer: EVP, Chf Clinical Develop Offc C/O IONIS PHARMACEUTICALS, 2855 GAZELLE CT, CARLSBAD CA 92010
Joseph Baroldi officer: Chief Business Officer C/O IONIS PHARMACEUTICALS, INC., C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eric Swayze officer: SVP, Research 2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Brett P Monia director, officer: Senior Vice President 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Richard S Geary officer: Senior Vice President 2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Elizabeth L Hougen officer: SVP, Finance and CFO 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
C Frank Bennett officer: Vice President 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
B Lynne Parshall director, officer: Executive Vice President, CFO 2855 GAZELLE COURT, CARLSBAD CA 92010
Joseph Iii Klein director C/O GENAISSANCE PHARMACEUTICALS INC, FIVE SCIENCE PARK, NEW HAVEN CT 06511
Allene M. Diaz director C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Spencer R Berthelsen director 2855 GAZELLE COURT, CARLSBAD CA 92010
Frederick T Muto director 2855 GAZELLE COURT, CARLSBAD CA 92010